证券研究报告 蜜雪集团 (2097 HK) 港股通 1H 高质量快步增长，龙头强者恒强 2025 年 8 月 29 日│中国香港 餐饮 | 目标价 (港币) | 590.22 | | --- | --- | | 收盘价 (港币 截至 8 月 28 日) | 435.00 | | 市值 (港币百万) | 165,134 | | 6 个月平均日成交额 (港币百万) | 317.85 | | 52 周价格范围 (港币) | 256.00-618.50 | | BVPS (人民币) | 55.98 | 华泰研究 中报点评 投资评级(维持): 买入 目标价(港币): 590.22 樊俊豪 研究员 SAC No. S0570524050001 SFC No. BDO986 曾珺 研究员 zengjun@htsc.com +(86) 21 2897 2228 洪洋* 联系人 SAC No. S0570125070021 hongyang@htsc.com +(86) 21 2897 2228 基本数据 股价走势图 (14) 41 95 150 204 Mar-25 May-25 Jun-25 Aug-25 (%) 蜜雪集团 ...

证 券 研 究 报 告 联易融科技-W（09959.HK）2025 年中报点评 推荐（维持） 拟大额回购彰显公司信心，国际业务有望打 造第二增长曲线 事项： ❖ 联易融科技发布 2025 年中报。25H1 实现营业收入 3.75 亿元（同比-9.3%）， 归母净利润-3.80 亿元，经调整净利润-3.72 亿元（24H1 为-1.89 亿元）。 评论： （1）电子债权凭证业务：25H1，促成融资额 1592.2 亿元（同比+38.6%），主 要由于聚焦于非地产客户的多级流转云融资额持续高增。多级流转云（客户为 核心企业）融资额为 1332.3 亿元（同比+54.4%），占 25H1 总融资额比例提升 至 65.5%。报告期内，为多家企业落地了订单融资等"弱信用链接解决方案"； E 链云（客户为金融机构）融资额为 259.9 亿元（同比-9.2%），主要由于公司 主动压降了 E 链云的部分低毛利业务。同时加速推进 AI Agent 核心模块迭代， 已在超过 24 家金融机构进行 SaaS 或本地化部署交付。 （2）资产证券化业务：25H1，促成融资额为 395.0 亿元（同比-3.8%）。AMS 云（客户为核心 ...

业绩增长强劲，ADC CRDMO 龙头地位稳固 事件： 2025 年 8 月 18 日，药明合联公布 2025 半年报：公司营收 27.01 亿元 （yoy+62.2%），增长的主要原因是客户数量及项目数量的增加；毛利率从 2024H1 的 32.1%增至 2025H1 的 36.1%，同比增长 4.0pct；净利润为 7.46 亿元（yoy+52.7%），经调整净利润（不含利息收入与支出）7.33 亿元 （yoy+69.6%），经调整净利润（包含利息支出及收入）为 8.01 亿元 （yoy+50.1%）。 港股公司报告 | 公司点评 药明合联（02268） 证券研究报告 随着 2025 年 7 月 DP3 制剂车间完成 GMP 放行，无锡基地进一步提升了其 一体化生产能力。DP5 制剂车间目前正在建设中并计划于 2027 年实现 GMP 放行。抗体及偶联原液生产线 BCM2 L2 自 2024 年 11 月启用以来，产能持 续加速扩张。 公司全球客户总数扩大至 563 家，2025 年上半年新增 64 家客户，其中 2024 年全球收入排名前 20 的制药公司中 13 家已与药明合联建立合作；综合 CMC（ ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price raised from 78 HKD to 101 HKD, indicating a potential upside of 21% [8]. Core Insights - The company has shown strong performance with a 27% year-on-year revenue growth in the first half of 2025, reaching 2.6 billion HKD, and an adjusted net profit growth of 80% to 91.42 million HKD, exceeding expectations due to better-than-expected single-store profitability [8]. - The company continues to expand its store network, adding 190 new stores in the first half of the year, with a total of 1,198 stores across 48 cities, indicating significant room for further expansion [8]. - Same-store sales have shown resilience, with a slight decline of 1% overall, while same-store revenue in first-tier cities has experienced positive growth [8]. Financial Data and Earnings Forecast - Revenue projections for the company are as follows: - 2023: 3,021 million HKD - 2024: 4,314 million HKD - 2025E: 5,403 million HKD - 2026E: 6,754 million HKD - 2027E: 8,294 million HKD - Year-on-year growth rates for revenue are projected at 51% for 2023, 41% for 2024, and gradually decreasing to 23% by 2027 [6]. - Adjusted net profit forecasts are: - 2023: 9 million HKD - 2024: 131 million HKD - 2025E: 190 million HKD - 2026E: 270 million HKD - 2027E: 352 million HKD - The adjusted net profit growth rates are exceptionally high, with a 1,394% increase expected in 2024 [6][9].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a projected stock price increase of 5% to 15% relative to the industry index over the next six months [5]. Core Views - The company's core business remains resilient despite a decline in net profit due to one-time non-cash losses and coal business impacts. The core profit showed a slight increase of 0.1% year-on-year, reflecting the robustness of the main operations [2][11]. - The company has a solid project reserve and orderly power generation construction, with a total installed capacity of 78,094 MW as of June 2025, split between thermal power (50.1%) and renewable energy (49.9%) [3]. - The company plans to invest HKD 56.8 billion in capital expenditures in 2025, focusing on renewable energy and thermal power projects, which will support future earnings growth [3][11]. Financial Performance - For the first half of 2025, the company reported a revenue of HKD 50.267 billion, a year-on-year decrease of 1.67%, and a net profit attributable to shareholders of HKD 7.872 billion, down 15.92% year-on-year [1][2]. - The company's earnings per share (EPS) for the first half of 2025 was HKD 1.52, a decrease of 22.05% year-on-year, with a return on equity (ROE) of 7.46%, down 2.89 percentage points year-on-year [1][2]. - The projected revenue for 2025 is HKD 107.056 billion, with a year-on-year growth of 1.68%, and a net profit of HKD 14.288 billion, reflecting a decline of 2.91% year-on-year [12]. Business Segments - The thermal power segment experienced a core profit of HKD 26.41 billion in the first half of 2025, a decrease of 2.7% year-on-year, but excluding coal impacts, the core profit from pure thermal power increased by 20.6% [2][10]. - The renewable energy segment saw significant growth, with wind and solar sales volumes increasing by 15.5% and 31.3% respectively in the first half of 2025, contributing to a core profit of HKD 5.637 billion, up 1.5% year-on-year [10][11].

Investment Rating - The report maintains a "Buy-A" rating for the company [2][8] Core Views - In the first half of 2025, the company achieved a revenue of 14.966 billion, representing a year-on-year growth of 15.3%, while the net profit attributable to shareholders was 3.177 billion, up 8.4% year-on-year [2][3] - The company's revenue growth was primarily driven by an increase in sales volume, although the profit growth lagged behind revenue due to a decline in gross margin and an increase in effective tax rate [3][4] - The company has seen a steady growth in sportswear and a remarkable performance in casual wear, with casual wear revenue growing significantly due to demand from markets in Japan, Europe, and other regions [3][4] Revenue Breakdown - Domestic market revenue slightly declined by 2.1%, while overseas markets experienced rapid growth, with revenue from the EU, the US, Japan, and other regions growing by 19.9%, 35.8%, 18.1%, and 18.7% respectively [4] - The company's four core customers accounted for 82.1% of total revenue, with significant growth in revenue from Uniqlo, Nike, Adidas, and Puma [4] Profitability and Costs - The gross margin decreased by 1.9 percentage points to 27.1% due to increased employee costs, while the inventory turnover improved with a decrease in inventory turnover days by 12 days [5][7] - The net profit margin decreased by 1.4 percentage points to 21.2% due to various factors including increased effective tax rate and government subsidies [7] Future Outlook - The company is expected to continue benefiting from its diversified product strategy and enhanced customer service capabilities, with a projected earnings per share of 4.40, 4.92, and 5.45 for 2025, 2026, and 2027 respectively [8][10] - The report anticipates that the negative impact of employee costs on gross margin will diminish in the second half of the year, and the company's vertical integration in fabric and garment production remains a core competitive advantage [8]

交银国际研究 财务模型更新 | 医药 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 29 日 | | --- | --- | --- | --- | --- | --- | | 港元 | 90.65 | 港元 | 105.00↑ | +15.8% | | | 信达生物 (1801 HK) | | | | | | 上市产品销售延续强势，管线全球开发进入关键阶段；上调目标价 公司产品收入强劲增长，再次验证公司优异的商业化管理能力和产品临床价 值。进入 2H25-2026 年，公司有诸多研发催化剂值得期待，包括多个国际多中 心关键临床的推进、玛仕度肽两项重磅 III 期数据读出。公司的全球化、多治 疗领域管线布局正在逐步成型，长期行业龙头地位稳固，上调目标价。 个股评级 买入 1 年股价表现 资料来源 : FactSet 8/24 12/24 4/25 8/25 -40% -20% 0% 20% 40% 60% 80% 100% 120% 140% 1801 HK 恒生指数 股份资料 | 52周高位 (港元) | 101.90 | | --- | --- | | 52周低位 (港元) | 30 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a significant increase in total revenue, with a year-on-year growth of 134% to 2.1 billion yuan, and total order amount increased by 84% to 1.7 billion yuan. The net profit attributable to shareholders improved from a loss of 170 million yuan in 2024 to a profit of 870 million yuan [2][8] - The company is leveraging AI and digital finance to drive new growth, with a focus on enhancing its product matrix and user experience [8] - The report highlights strong cost control, with various expense ratios declining, indicating effective management of operational costs [8] Summary by Sections Financial Performance - Total revenue for 2023 is projected at 1,965 million yuan, with a year-on-year growth of 6.23%. By 2025, revenue is expected to reach 3,907 million yuan, reflecting a growth of 69.42% [1] - The net profit attributable to shareholders is forecasted to be 1,384 million yuan in 2025, a substantial increase of 408.07% compared to 2024 [1] - The latest diluted EPS is projected to be 3.21 HKD per share in 2025, with a P/E ratio of 22.84 [1] Business Strategy - The company is focusing on integrating its existing products into a more cohesive offering, enhancing user experience and operational efficiency [8] - The introduction of new products such as "Easy Knowledge Stock Road" learning machine and AI investment advisory services aims to attract a broader user base [8] - The company is exploring opportunities in the digital finance sector, including investments in digital asset services and innovative financial advisory models [8] Market Position - The company is positioned to strengthen its leading role in the rapidly expanding online investment education market, with a growing number of paying customers [8] - The report anticipates continued robust growth in the company's various business segments, supported by increased investment in research and development [8]

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company reported a strong revenue growth of 18.5% year-on-year, reaching HKD 10.32 billion in the first half of 2025, with a net profit increase of 9.8% to HKD 706 million [1][2] - The growth in revenue is primarily driven by the import and export of tobacco leaf products and cigarette exports, while the net profit increase is attributed to improved profitability in cigarette and tobacco leaf exports, alongside a significant reduction in financing costs by 28% [1][2] - The company plans to distribute an interim dividend of HKD 0.19 per share, reflecting a 27% increase [1] Revenue Breakdown - Tobacco Leaf Imports: Revenue increased by 23.5% to HKD 8.4 billion, with an import volume of 97,900 tons (+2.5%) and an average import price of HKD 85,800 per ton (+20.5%). The gross margin decreased to 8.2% due to cost increases outpacing sales price increases [1] - Tobacco Leaf Exports: Revenue rose by 25.9% to HKD 1.16 billion, with export volume of 38,500 tons (+12.7%) and an average export price of HKD 30,000 per ton (+11.7%). The gross margin improved to 5.5% [2] - Cigarette Exports: Revenue slightly increased by 0.8% to HKD 550 million, with export volume declining by 7.9% to 1.019 billion sticks, while the average export price rose by 9.4% to HKD 0.54 per stick. The gross margin improved to 25.7% [2] - New Tobacco Exports: Revenue fell by 66.5% to HKD 15 million, with export volume down by 65.4% to 81 million sticks, primarily due to geopolitical conflicts and regulatory changes [3] - Brazilian Operations: Revenue decreased by 50.3% to HKD 195 million, with export volume down by 34.8% to 7,900 tons, affected by extreme weather and product mix changes [3] Financial Forecasts - The company has raised its profit forecasts, expecting net profits of HKD 940 million, HKD 1.04 billion, and HKD 1.18 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 9.6%, 11.4%, and 12.9% [1][4] - The diluted EPS is projected to be HKD 1.35, HKD 1.51, and HKD 1.70 for the same years, with corresponding P/E ratios of 27, 25, and 22 [1][4]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 78.83 HKD [5][3]. Core Insights - The company reported a revenue of 499 million CNY and a net profit of -79 million CNY for the first half of 2025. The core product, IL-4R monoclonal antibody Siponimod, is progressing well in commercialization, achieving sales of 170 million CNY in the first half of 2025. The product has been approved for three indications and is expected to enter negotiations for inclusion in the medical insurance directory, which could accelerate sales growth in the domestic market [1][3]. - The company has a diverse early-stage pipeline, with several products in various stages of clinical trials, including CM512 for moderate to severe atopic dermatitis and chronic rhinosinusitis with nasal polyps, and CM336 for relapsed or refractory multiple myeloma [2][3]. Financial Projections - Revenue projections for the company are estimated at 750 million CNY in 2025, 1.11 billion CNY in 2026, and 2.08 billion CNY in 2027. Net profits are expected to be -440 million CNY in 2025, -410 million CNY in 2026, and a positive 80 million CNY in 2027 [3][9]. - The company is expected to achieve a gross margin of 92% and a net margin of 3.6% by 2027, indicating a significant improvement in profitability as revenues grow [11][15]. Market Performance - The company's stock price was 66.50 HKD as of August 28, 2025, with a 12-month price range of 27.85 to 74.75 HKD. The stock has shown a relative return of 49.1% over the past three months and 68.5% over the past year [5][6]. Clinical Pipeline - The company has multiple products in its early pipeline, including CM512, CM518D1, CM336, and CM383, which are in various phases of clinical trials targeting conditions such as asthma, chronic obstructive pulmonary disease, and Alzheimer's disease [2][3].